Wednesday, May 31, 2023 | Back issues
Courthouse News Service Courthouse News Service


MANHATTAN - The Second Circuit affirmed dismissal Friday of two securities complaints against Genzyme-successor Sanofi regarding statements about the multiple sclerosis drug Lemtrada.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.